Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
20.32
-0.28 (-1.36%)
At close: Mar 28, 2025, 4:00 PM
20.49
+0.17 (0.82%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 35.44, with a low estimate of 30 and a high estimate of 44. The average target predicts an increase of 74.41% from the current stock price of 20.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 5 | 6 |
| Buy | 0 | 1 | 2 | 2 | 2 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 6 | 7 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $23 → $35 | Hold → Strong Buy | Upgrades | $23 → $35 | +72.24% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 21, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $30 | Buy | Initiates | $30 | +47.64% | Mar 12, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +106.69% | Feb 28, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $32 | Buy | Reiterates | $32 | +57.48% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
30.28M
EPS This Year
-0.42
from -0.31
EPS Next Year
-0.58
from -0.42
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 174.1M | 449.4M | ||
| Avg | n/a | 30.3M | 193.6M | ||
| Low | n/a | -81.2M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,384.2% | ||
| Avg | - | - | 539.3% | ||
| Low | - | - | -67.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.41 | -0.48 | -0.29 | ||
| Avg | -0.42 | -0.58 | -0.57 | ||
| Low | -0.44 | -0.70 | -0.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.